Nuvation Bio Inc 投资支付的现金 : $ -703.37 (2023年12月 TTM)
Nuvation Bio Inc投资支付的现金(Purchase Of Investment)的相关内容及计算方法如下:
投资支付的现金是指企业购买长期和短期投资项目所支付的现金。
截至2023年12月, Nuvation Bio Inc 过去一季度 的 投资支付的现金 为 $ -148.74。 Nuvation Bio Inc 最近12个月的 投资支付的现金 为 $ -703.37。
点击上方“历史数据”快速查看Nuvation Bio Inc 投资支付的现金的历史走势;
点击上方“解释说明”快速查看关于Nuvation Bio Inc 投资支付的现金的详细说明;
点击上方“相关词条”快速查看与投资支付的现金相关的其他指标。
Nuvation Bio Inc 投资支付的现金 (NUVB.WS 投资支付的现金) 历史数据
Nuvation Bio Inc 投资支付的现金的历史年度,季度/半年度走势如下:
Nuvation Bio Inc 投资支付的现金 年度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
投资支付的现金 | -143.29 | -609.30 | -520.31 | -703.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nuvation Bio Inc 投资支付的现金 季度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
投资支付的现金 | -123.18 | -254.45 | -131.67 | -131.00 | -119.93 | -137.71 | -236.97 | -206.83 | -110.83 | -148.74 |
Nuvation Bio Inc 投资支付的现金 (NUVB.WS 投资支付的现金) 解释说明
投资支付的现金是指企业购买长期和短期投资项目所支付的现金。
Nuvation Bio Inc 投资支付的现金 (NUVB.WS 投资支付的现金) 相关词条
感谢查看价值大师中文站为您提供的Nuvation Bio Inc投资支付的现金的详细介绍,请点击以下链接查看与Nuvation Bio Inc投资支付的现金相关的其他词条:
Nuvation Bio Inc (NUVB.WS) 公司简介
一级行业:医疗保健
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).